Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.

Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, Harbeck N; West German Study Group PlanB Investigators.

J Clin Oncol. 2019 Apr 1;37(10):799-808. doi: 10.1200/JCO.18.00028. Epub 2019 Feb 20.

PMID:
30785826
2.

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2019 May;175(1):265-266. doi: 10.1007/s10549-018-05105-8.

3.

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.

J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.

PMID:
28682681
4.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29. Erratum in: Breast Cancer Res Treat. 2019 Jan 10;:.

5.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. No abstract available.

PMID:
27634692
6.

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N; EC-Doc investigators (West German Study Group/AGO-B).

Ann Oncol. 2016 Jun;27(6):1035-40. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18.

PMID:
27022068
7.

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.

Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates RE, Cowens W, Hornberger J, Pelz E, Harbeck N.

Curr Med Res Opin. 2016 Jul;32(7):1217-24. doi: 10.1185/03007995.2016.1166102. Epub 2016 Mar 30.

PMID:
26971372
8.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N.

J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.

PMID:
26926676
9.

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.

Ataseven B, Gunesch A, Eiermann W, Kates RE, Högel B, Knyazev P, Ullrich A, Harbeck N.

Onco Targets Ther. 2014 Oct 6;7:1723-31. doi: 10.2147/OTT.S62676. eCollection 2014.

10.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899.

PMID:
24827128
11.

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Dünnebacke J, Belzl N, Augustin D, Kates RE, Harbeck N; West German Study Group.

Ann Oncol. 2014 Jan;25(1):75-80. doi: 10.1093/annonc/mdt505.

PMID:
24356620
13.

Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.

Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N.

Breast Cancer Res Treat. 2013 Apr;138(3):839-50. doi: 10.1007/s10549-013-2496-z. Epub 2013 Apr 9.

PMID:
23568480
14.

3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.

Warm M, Duda V, Eichler C, Harbeck N, Gossmann A, Thomas A, Hoopmann M, Ohlinger R, Breidenbach M, Kates RE.

Anticancer Res. 2011 Nov;31(11):4039-42.

PMID:
22110239
15.

Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition.

Krüger A, Kates RE, Edwards DR.

Biochim Biophys Acta. 2010 Jan;1803(1):95-102. doi: 10.1016/j.bbamcr.2009.09.016. Epub 2009 Oct 1. Review.

16.
17.

Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer.

Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S, Allgayer H.

Clin Cancer Res. 2007 Feb 15;13(4):1123-32.

18.

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.

Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA.

Clin Breast Cancer. 2004 Dec;5(5):348-52. Review.

PMID:
15585071
19.

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.

Thromb Haemost. 2004 Mar;91(3):450-6. Review.

PMID:
14983219
20.

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N.

J Clin Oncol. 2003 Mar 15;21(6):1022-8.

PMID:
12637466
21.

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C.

Clin Breast Cancer. 2002 Aug;3(3):196-200. Review.

PMID:
12196277
22.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.

Cancer Res. 2002 Aug 15;62(16):4617-22.

24.
25.

Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.

Harbeck N, Krüger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Jänicke F.

Onkologie. 2001 Jun;24(3):238-44. Review. English, German.

PMID:
11455216
26.

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.

Haas DW, Clough LA, Johnson BW, Harris VL, Spearman P, Wilkinson GR, Fletcher CV, Fiscus S, Raffanti S, Donlon R, McKinsey J, Nicotera J, Schmidt D, Shoup RE, Kates RE, Lloyd RM Jr, Larder B.

AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1491-502.

PMID:
11054262
27.

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M.

Breast Cancer Res Treat. 1999 Mar;54(2):147-57.

PMID:
10424405
28.

Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.

Jung D, Griffy K, Dorr A, Raschke R, Tarnowski TL, Hulse J, Kates RE.

J Clin Pharmacol. 1998 Nov;38(11):1057-62.

PMID:
9824788
29.

Clinical pharmacology of intravenous enoximone: pharmacodynamics and pharmacokinetics in patients with heart failure.

Smith NA, Kates RE, Lebsack C, Ruder MA, Mead RH, Bekele T, Okerholm RA, Rubin GM, Winkle RA.

Am Heart J. 1991 Sep;122(3 Pt 1):755-63.

PMID:
1831585
30.

Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure.

Ruder MA, Lebsack C, Winkle RA, Mead RH, Smith N, Kates RE.

J Clin Pharmacol. 1991 Aug;31(8):702-8.

PMID:
1831816
31.

Opioids potentiate contractile response of rabbit myocardium to the beta adrenergic agonist isoproterenol.

Kindman LA, Kates RE, Ginsburg R.

J Cardiovasc Pharmacol. 1991 Jan;17(1):61-7.

PMID:
1708057
32.

Pharmacodynamics of enoximone during intravenous infusion.

Winkle RA, Smith NA, Ruder MA, Mead RH, Lebsack C, Bekele T, Kates RE, Rubin J, Okerholm R.

Int J Cardiol. 1990 Jul;28 Suppl 1:S1-2.

PMID:
2145232
33.

Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo.

Anderson KP, Walker R, Dustman T, Lux RL, Ershler PR, Kates RE, Urie PM.

Circulation. 1989 Apr;79(4):948-58.

PMID:
2924420
34.

Update: cardiac antiarrhythmic drugs.

Liem LB, Kates RE.

Compr Ther. 1989 Apr;15(4):17-27. Review.

PMID:
2495883
35.

In vivo evaluation of the effects of altered cyclosporine metabolism on its immunosuppressive potency.

Babany G, Morris RE, Babany I, Shepherd S, Kates RE.

J Pharmacol Exp Ther. 1989 Mar;248(3):893-9.

PMID:
2649657
36.

Effect of albumin on the electrophysiologic stability of isolated perfused rabbit hearts.

Kates RE, Yee YG, Hill I.

J Cardiovasc Pharmacol. 1989 Jan;13(1):168-72.

PMID:
2468930
37.

Pharmacodynamics of procainamide in patients with ventricular tachyarrhythmias.

Liem LB, Yee YG, Swerdlow CD, Kates RE.

J Clin Pharmacol. 1988 Nov;28(11):984-9.

PMID:
3243920
38.
39.
40.

Pharmacodynamics and pharmacokinetics of oral pirmenol.

Ellenbogen KA, Roark SF, Sintetos AL, Smith MS, McCarthy EA, Smith WM, Kates RE, Pritchett EL.

Clin Pharmacol Ther. 1987 Oct;42(4):405-10.

PMID:
3665339
41.

Interaction between warfarin and propafenone in healthy volunteer subjects.

Kates RE, Yee YG, Kirsten EB.

Clin Pharmacol Ther. 1987 Sep;42(3):305-11.

PMID:
3621785
42.

Influence of hepatic dysfunction on the pharmacokinetics of propafenone.

Lee JT, Yee YG, Dorian P, Kates RE.

J Clin Pharmacol. 1987 May-Jun;27(5):384-9.

PMID:
3693582
43.

Cyclosporine serum concentrations soon after heart or heart-lung transplantation.

Aziz S, Oyer PE, Kates RE.

J Clin Pharmacol. 1986 Nov-Dec;26(8):652-7.

PMID:
3098805
44.

Pharmacodynamic modeling of antiarrhythmic drug effects--application to 3-methoxy-O-demethyl encainide.

Dorian P, Davy JM, Kates RE.

J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1217-22.

PMID:
2434749
45.

Influence of protein binding on the myocardial uptake and pharmacodynamics of propafenone.

Gillis AM, Kates RE.

J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1163-7.

PMID:
2434742
46.

Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.

Harrison DC, Kates RE, Quart BD.

Am J Cardiol. 1986 Aug 29;58(5):66C-73C.

PMID:
3092622
47.
48.

Myocardial uptake kinetics and pharmacodynamics of propafenone in the isolated perfused rabbit heart.

Gillis AM, Kates RE.

J Pharmacol Exp Ther. 1986 Jun;237(3):708-12.

PMID:
3712276
49.

Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog.

Davy JM, Dorian P, Kantelip JP, Harrison DC, Kates RE.

J Pharmacol Exp Ther. 1986 Jun;237(3):907-11.

PMID:
3086540
50.

Effects of encainide and its metabolites on energy requirements for defibrillation.

Fain ES, Dorian P, Davy JM, Kates RE, Winkle RA.

Circulation. 1986 Jun;73(6):1334-41.

PMID:
3084128

Supplemental Content

Loading ...
Support Center